Evaluation of CpG-ODN-adjuvanted polyanhydride-based intranasal influenza nanovaccine in pigs

Dhakal, Santosh; Ghimire, Shristi; Renu, Sankar; Ross, Kathleen A.; Lakshmanappa, Yashavanth Shaan; Hogshead, Bradley T.; Bernardo, Pauline; Lee, C.W.; Wannemuehler, Michael J.; Narasimhan, Balaji; Renukaradhya, G.J.

doi:10.1016/j.vetmic.2019.108401

Cited by 20 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viral fever, viral shedding and lung virus titers were also reduced. [ 111 ] Intranasal administration presents antigens in a manner similar to natural infection with large surface area, high vascularization and lower enzymatic and chemical degradation than oral route. This, in combination with the successful demonstration of NP vaccine in a larger animal model show that the field of NP vaccine therapeutics is greatly improving.…”

Section: Nanoparticles Are An Advantageous Methods For Delivering Nucleic Acid Vaccinesmentioning

confidence: 99%

“…However, the authors note that expression level of the exogenous genes with this formulation was low and resulting immunogenicity was weak, and therefore improvements can be made with the NP formulation and MN composition. [110] Dhakal and co-workers developed a polyanhydride nanoparticle-based inactivated intranasal swine influenza vaccine [111] (termed KAg + CpG-nanovaccine) encapsulating inactivated/killed soluble antigen (KAg) and Toll-like receptor (TLR)-9 agonist (CpG-ODN). CpG oligodeoxynucleotides bind to and activate Toll-like receptor 9 (TLR9), which triggers an innate immune response that supports the subsequent development of adaptive immunity and improve antigen presentation as well as cellular and humoral immune response.…”

Section: Polymeric Nanoparticle Systemsmentioning

confidence: 99%

See 1 more Smart Citation

Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery

Gao

et al. 2021

Adv Healthcare Materials

183

139

View full text Add to dashboard Cite

Nucleic acid vaccines are a method of immunization aiming to elicit immune responses akin to live attenuated vaccines. In this method, DNA or messenger RNA (mRNA) sequences are delivered to the body to generate proteins, which mimic disease antigens to stimulate the immune response. Advantages of nucleic acid vaccines include stimulation of both cell-mediated and humoral immunity, ease of design, rapid adaptability to changing pathogen strains, and customizable multiantigen vaccines. To combat the SARS-CoV-2 pandemic, and many other diseases, nucleic acid vaccines appear to be a promising method. However, aid is needed in delivering the fragile DNA/mRNA payload. Many delivery strategies have been developed to elicit effective immune stimulation, yet no nucleic acid vaccine has been FDA-approved for human use. Nanoparticles (NPs) are one of the top candidates to mediate successful DNA/mRNA vaccine delivery due to their unique properties, including unlimited possibilities for formulations, protective capacity, simultaneous loading, and delivery potential of multiple DNA/mRNA vaccines. This review will summarize the many varieties of novel NP formulations for DNA and mRNA vaccine delivery as well as give the reader a brief synopsis of NP vaccine clinical trials. Finally, the future perspectives and challenges for NP-mediated nucleic acid vaccines will be explored.

show abstract

Section: Nanoparticles Are An Advantageous Methods For Delivering Nucleic Acid Vaccinesmentioning

confidence: 99%

Section: Polymeric Nanoparticle Systemsmentioning

confidence: 99%

Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery

Gao

et al. 2021

Adv Healthcare Materials

183

139

View full text Add to dashboard Cite

show abstract

“…The authors of the study reported that the PA nanoparticle-based vaccine-induced protective immunity against a heterologous IAV challenge in pigs . The encapsulation of antigen (KAg) of killed viral influenza virus H1N2-OH10 into the poly(CPTEG-CPH) (20:80) nanoparticles that coencapsulating with KAg and toll-like receptors (TLR)-9 adjuvants (CpG-ODN) is an effective strategy for the intranasal immunization in pigs against swine influenza A virus . In addition, the potential Influenza A virus vaccines are developed based on pentablock copolymer hydrogels (Pluronic F127-cationicpolydiethylaminoethyl methacrylate) and PA nanoparticles (poly(CPTEG-CPH) (20:80)) to deliver the a recombinant equine H3N8 hemagglutinin trimer (rH33).…”

Section: Applicationsmentioning

confidence: 99%

Polyanhydride Chemistry

Reddy

Domb

2022

Biomacromolecules

View full text Add to dashboard Cite

Polyanhydrides (PAs) are a class of synthetic biodegradable polymers employed as controlled drug delivery vehicles. They can be synthesized and scaled up from low-cost starting materials. The structure of PAs can be manipulated synthetically to meet desirable characteristics. PAs are biocompatible, biodegradable, and generate nontoxic metabolites upon degradation, which are easily eliminated from the body. The rate of water penetrating into the polyanhydride (PA) matrix is slower than the anhydride bond cleavage. This phenomenon sets PAs as "surface-eroding drug delivery carriers." Consequently, a variety of PA-based drug delivery carriers in the form of solid implants, pasty injectable formulations, microspheres, nanoparticles, etc. have been developed for the sustained release of small molecule drugs, and vaccines, peptide drugs, and nucleic acid-based active agents. The rate of drug delivery is often controlled by the polymer erosion rate, which is influenced by the polymer structure and composition, crystallinity, hydrophobicity, pH of the release medium, device size, configuration, etc. Owing to the above-mentioned interesting physicochemical and mechanical properties of PAs, the present review focuses on the advancements made in the domain of synthetic biodegradable biomedical PAs for therapeutic delivery applications. Various classes of PAs, their structures, their unique characteristics, their physicochemical and mechanical properties, and factors influencing surface erosion are discussed in detail. The review also summarizes various methods involved in the synthesis of PAs and their utility in the biomedical domain as drug, vaccine, and peptide delivery carriers in different formulations are reviewed.

show abstract

“…Since then, intranasal administration of IFN-I has been repeatedly explored as prophylactic measure against respiratory infections with variable results that mostly depended on the dose and on the type of patients [55]. The intranasal route has also been explored for the delivery of IFN-I [56] or IFN-I-inducers [57] as adjuvants for influenza vaccines in animal models. In all these studies, intranasal IFN-I was well tolerated and devoid of any evident toxicity.…”

Section: Mucosal Delivery Of Ifn-i: Is This Strategy Ready For Efficimentioning

confidence: 99%

Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?

Aricò

Bracci

Castiello

et al. 2020

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) first emerged in late 2019 in China. At the time of writing, its causative agent SARS-CoV-2 has spread worldwide infecting over 9 million individuals and causing more than 460,000 deaths. In the absence of vaccines, we are facing the dramatic challenge of controlling COVID-19 pandemic. Among currently available drugs, type I Interferons (IFN-I)-mainly IFN-α and β-represent ideal candidates given their direct and immune-mediated antiviral effects and the long record of clinical use. However, the best modalities of using these cytokines in SARS-CoV-2 infected patients is a matter of debate. Here, we discuss how we can exploit the current knowledge on IFN-I system to tailor the most promising dosing, timing and route of administration of IFN-I to the disease stage, with the final aim of making these cytokines a valuable therapeutic strategy in today's fight against COVID-19 pandemic.

show abstract

Evaluation of CpG-ODN-adjuvanted polyanhydride-based intranasal influenza nanovaccine in pigs

Cited by 20 publications

References 24 publications

Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery

Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery

Polyanhydride Chemistry

Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?

Contact Info

Product

Resources

About